BNP Paribas Financial Markets Makes New Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

BNP Paribas Financial Markets bought a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 203,853 shares of the company's stock, valued at approximately $3,908,000. BNP Paribas Financial Markets owned about 0.26% of Viridian Therapeutics as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in VRDN. Barclays PLC lifted its position in shares of Viridian Therapeutics by 113.1% in the 3rd quarter. Barclays PLC now owns 125,397 shares of the company's stock worth $2,851,000 after purchasing an additional 66,550 shares during the period. SG Americas Securities LLC increased its stake in shares of Viridian Therapeutics by 89.1% in the fourth quarter. SG Americas Securities LLC now owns 31,085 shares of the company's stock worth $596,000 after acquiring an additional 14,644 shares during the period. Moody Aldrich Partners LLC acquired a new stake in shares of Viridian Therapeutics in the fourth quarter worth $1,125,000. Vanguard Group Inc. boosted its holdings in Viridian Therapeutics by 4.0% during the fourth quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company's stock worth $88,087,000 after buying an additional 174,952 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in Viridian Therapeutics by 3.3% during the fourth quarter. Principal Financial Group Inc. now owns 178,444 shares of the company's stock valued at $3,421,000 after purchasing an additional 5,634 shares in the last quarter.

Viridian Therapeutics Stock Performance

NASDAQ VRDN traded up $0.24 during trading hours on Tuesday, reaching $13.06. The company's stock had a trading volume of 256,482 shares, compared to its average volume of 1,189,464. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The business has a 50-day simple moving average of $13.33 and a 200 day simple moving average of $17.04. Viridian Therapeutics, Inc. has a 52 week low of $9.90 and a 52 week high of $27.20. The stock has a market cap of $1.07 billion, a PE ratio of -3.03 and a beta of 0.57.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. The firm had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.16 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The company's quarterly revenue was up .0% compared to the same quarter last year. Equities research analysts predict that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

VRDN has been the subject of several recent analyst reports. The Goldman Sachs Group cut their price objective on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Royal Bank of Canada lowered their price objective on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. JMP Securities decreased their price target on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. HC Wainwright restated a "buy" rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. Finally, Needham & Company LLC reduced their price objective on shares of Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat.com, Viridian Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $36.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.